AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Myasthenia Gravis Pipeline Review, H2 2019 - ResearchAndMarkets.com

November 22, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Nov 22, 2019--

The “Myasthenia Gravis - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Myasthenia Gravis (Immunology) pipeline landscape.

The provides comprehensive information on the therapeutics under development for Myasthenia Gravis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myasthenia Gravis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 6, 5, 16, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Myasthenia Gravis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Report Scope

Reasons to Buy

Featured News & Press Releases

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/c2v8ul

View source version on businesswire.com:https://www.businesswire.com/news/home/20191122005362/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH GENERAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/22/2019 10:20 AM/DISC: 11/22/2019 10:20 AM

http://www.businesswire.com/news/home/20191122005362/en